LS
NTLA icon

Leelyn Smith’s Intellia Therapeutics NTLA Stock Holding History

Leelyn Smith’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-153
Closed -$5.34K – 313
2022
Q4 		$5.34K Hold
153
– – ﹤0.01% 363
2022
Q3 		$9K Hold
153
– – ﹤0.01% 305
2022
Q2 		$8K Buy
+153
New +$7.77K ﹤0.01% 305

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Leelyn Smith's NTLA Position: Q1 2023 in Review

Leelyn Smith sold out of Intellia Therapeutics (NTLA) in Q1 2023, closing a stake of 153 shares — an estimated $5.34K sold.

Leelyn Smith first reported a position in NTLA in Q2 2022 and held it in 3 quarters. The position peaked at $9K in Q3 2022. 290 funds tracked by Wall St. Rank hold NTLA as of Q1 2023.

  • Leelyn Smith reported no remaining Intellia Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Leelyn Smith sold 153 Intellia Therapeutics shares in Q1 2023, an estimated $5.34K.
  • Leelyn Smith first reported a position in Intellia Therapeutics in Q2 2022 and held it in 3 quarters.
  • Leelyn Smith's Intellia Therapeutics position peaked at $9K in Q3 2022.
  • 290 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2023.

Based on Leelyn Smith's 13F filing for Q1 2023, filed 12 May 2023.